USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Autifony Therapeutics Limited

USPTO PatentsView assignee record - 25 granted patents across 5 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07D (Heterocyclic Compounds).

RSS updates for this company

The verdict

According to USPTO PatentsView, Autifony ranks #11,930 of 49,997 tracked US assignees by granted-patent volume, with 25 patents across 5 technology areas.

#11,930
of 49,997 US assignees by volume
27th percentile
by Innovation Score (28.5/100)
11.8
avg claims per patent
-15%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R11930 · Foreign Corporation #11,930 · 25 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-PAR · TYPE-FRNCORP · VEL-DOWN · BOOK-FULL

  • GRANTS-SMALL 25 grants
  • UPPER-Q #11,930/49,997
  • PHOTO-FINISH Arla Foods Amba
  • CPC-NARROW C07D · 5 areas
  • INNOV-THIN 28.5/100
  • CLAIMS-PAR 11.8 claims/avg
  • TYPE-FRNCORP Foreign Corp
  • VEL-DOWN -15% vel
  • BOOK-FULL 10/10 fields

Nearest grant-volume peer: Arla Foods Amba (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Autifony’s 28.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Innovation-score neighbourhood around Autifony

Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.

score

What this shows Autifony's Innovation Score is 28.5/100 (27th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Source USPTO PatentsView, PlainPatent Innovation Score As of 2015–2025

Does more volume mean deeper claims for Autifony?

Each dot is one of Autifony’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Autifony’s own 11.8 claims/patent is at or below the 12.8 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Autifony vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView. 2×2 strategic matrix plotting 9 entities by Granted patents (volume) (X) and Avg claims / patent (Y), with a crosshair dividing the plot into four quadrants. Volume + depthSelective & thoroughVolume over depthLean filer 24.924.92525.1 510152025 Granted patents (volume) Avg claims / patent Arla Foods Amba - 25, 18.4Arla Foods AmbaAspen Surgical Products, Inc. - 25, 10Aspen Surgical Pr…Attopsemi Technology Co., Ltd - 25, 22.44Attopsemi Technol…Aurobindo Pharma Ltd - 25, 6.64Aurobindo PharmaAventics GmbH - 25, 12.76AventicsBarilla G. & R. Fratelli S.p.A. - 25, 8.16Barilla G & R Fra…Bedoukian Research, Inc. - 25, 15.16Bedoukian ResearchBharat Petroleum Corporation Limited - 25, 13.84Bharat PetroleumAutifony Therapeutics Limited - 25, 11.84Autifony Therapeu…
Autifony vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Autifony's grants concentrate

Autifony Therapeutics Limited is a focused PatentsView assignee: 5 CPC subclasses with 100% of grants classified under C07D (Heterocyclic Compounds). Peak complete grant year is 2020 (4 grants) versus a trough of 1 in 2019. By volume, Autifony sits between Arla Foods Amba and Bharat Petroleum Corporation Limited.

Autifony's three-year grant acceleration

Autifony Therapeutics Limited shows 3 grants in 2022–2024 against only 9 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Who files at Autifony's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Autifony holds 25 patents at rank #11,931, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Autifony

By rank, the assignees closest to #11,931 in granted patent volume.

Leaders in C07D (Heterocyclic Compounds)

Other assignees with the most granted patents in Autifony's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Autifony, neither rank-band nor same-CPC leaders (those blocks stay above). In C07D (Heterocyclic Compounds), Autifony ranks #342 of 3,165 assignees by patent count in that subclass.

Autifony's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

28 27th percentile higher than 27% of 49,997 US assignees

This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

012345 2015201620172018201920202021202320242025 1
USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table
Autifony Therapeutics Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2015 3 12.0%
2016 3 12.0%
2017 3 12.0%
2018 3 12.0%
2019 1 4.0%
2020 4 16.0%
2021 4 16.0%
2023 2 8.0%
2024 1 4.0%
2025partial year 1 4.0%

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

What to do with this data

Autifony Therapeutics Limited's patent record in context - here's where to go next.

  • Autifony Therapeutics Limited's lead technology class is C07D (Heterocyclic Compounds), 100% of its portfolio - see every assignee active in that class. Explore C07D
  • Ranked #11,930 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
  • Compare Autifony Therapeutics Limited against Arla Foods Amba, an assignee filing at a similar volume. Compare portfolios
  • Innovation Score of 28.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.